Tirzepatide: How One Peptide Activates Two Receptors
A 39-residue sequence engineered from the GIP backbone to bind two different receptors, with a fatty diacid to survive renal clearance.
Tirzepatide is a 39-residue synthetic peptide that acts at two receptors — GIP and GLP-1 — rather than one. The interesting chemistry is how a single sequence was engineered to do that, because dual agonism is not something that happens by accident.
The design problem
GIP and GLP-1 are both incretin peptides and both belong to the glucagon superfamily, so they share structural features. They are not, however, interchangeable: each has its own receptor with its own binding preferences.
Building one molecule that activates both means finding a sequence close enough to each native ligand to bind its receptor, while being neither. The approach taken was to start from the GIP backbone and substitute residues at positions where GLP-1 differs and where the GLP-1 receptor is tolerant.
The modifications
- α-aminoisobutyric acid at positions 2 and 13. Aib at position 2 blocks dipeptidyl peptidase-4, the same solution used in semaglutide. Aib is also strongly helix-promoting — its two alpha-methyl groups restrict backbone rotation — so the second Aib stabilises the helical conformation both receptors recognise.
- A C20 fatty diacid at Lys20, attached through a γ-glutamic acid and two AEEA units. As with semaglutide, this binds serum albumin reversibly, shielding the peptide from renal clearance and producing a half-life measured in days rather than minutes.
- C-terminal amidation, removing the free carboxylate and blocking carboxypeptidase attack.
- Sequence substitutions at positions where the GIP and GLP-1 receptors’ requirements diverge, tuning the balance of activity between the two.
Molecular weight is approximately 4813 g/mol.
Why it is analytically demanding
Thirty-nine residues, two non-proteinogenic amino acids, a multi-step side-chain conjugation and a C-terminal amide. Each of those is a place where synthesis can go incompletely right.
| What can go wrong | What detects it |
|---|---|
| Missing residue (deletion sequence) | Mass spectrometry — HPLC often will not resolve it |
| Incomplete or absent acylation | Mass spectrometry — large mass difference |
| Free acid instead of C-terminal amide | Mass spectrometry — +1 Da |
| Closely related synthesis by-products | HPLC peak-area integration |
The practical conclusion is that for a molecule of this complexity, a purity figure without a mass confirmation is close to meaningless. HPLC tells you how much of one thing is present; it does not tell you that the thing is what the label says.
Handling
The lipid side chain makes tirzepatide amphiphilic, which means it is more prone than a simple hydrophilic peptide to adsorb onto surfaces and to unfold at air–liquid interfaces. Reconstitute by running solvent down the vial wall, swirl gently, never shake or vortex, and use low-binding tubes for dilute solutions. Refrigerate after reconstitution and aliquot rather than freeze–thaw.
Our reconstitution guide and aggregation note cover the technique in detail.
Tirzepatide is supplied strictly for laboratory research. We do not provide dosing information and nothing here describes use in humans. Every batch is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.